Collegium Pharmaceutical, Inc. Cost, Direct Material
Collegium Pharmaceutical, Inc. (COLL) reported Cost, Direct Material of $563.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostDirectMaterial · last filed 2023-11-07
- Collegium Pharmaceutical, Inc. cost, direct material for the quarter ending 2023-09-30 was $563.00K.
- Collegium Pharmaceutical, Inc. cost, direct material for the quarter ending 2023-06-30 was $155.00K.
- Collegium Pharmaceutical, Inc. cost, direct material for the quarter ending 2023-03-31 was $906.00K.
- Collegium Pharmaceutical, Inc. cost, direct material for fiscal 2022 was $1.81M.
| Period end | Cost, Direct Material 3 month | Cost, Direct Material 6 month | Cost, Direct Material 9 month | Cost, Direct Material 12 month |
|---|---|---|---|---|
| 2023-09-30 | $563.00K 10-Q · filed 2023-11-07 | $718.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.62M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $155.00K 10-Q · filed 2023-08-03 | $1.06M 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $906.00K 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $1.81M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |